654 related articles for article (PubMed ID: 27140405)
1. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib for the treatment of ulcerative colitis.
Fernández-Clotet A; Castro-Poceiro J; Panés J
Expert Rev Clin Immunol; 2018 Nov; 14(11):881-892. PubMed ID: 30285500
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibition in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
[TBL] [Abstract][Full Text] [Related]
9. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
10. Update on Janus kinase antagonists in inflammatory bowel disease.
Boland BS; Sandborn WJ; Chang JT
Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
[TBL] [Abstract][Full Text] [Related]
11. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
[TBL] [Abstract][Full Text] [Related]
14. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
15. [JAK inhibitor].
Yamaoka K; Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
19. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.
Varyani F; Argyriou K; Phillips F; Tsakiridou E; Moran GW
Drug Des Devel Ther; 2019; 13():4091-4105. PubMed ID: 31819376
[TBL] [Abstract][Full Text] [Related]
20. The use of tofacitinib in the treatment of inflammatory bowel disease.
Weisshof R; Golan MA; Yvellez OV; Rubin DT
Immunotherapy; 2018 Aug; 10(10):837-849. PubMed ID: 29701124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]